Lindsey Shapiro, PhD, science writer —

The first patient has been dosed in an open-label dose optimization trial of bryostatin, an investigational treatment for Alzheimer’s disease. According to the therapy’s developer, Synaptogenix — previously called Neurotrope — the dose-finding trial will prepare the company to move forward with bryostatin’s next phase of clinical…

The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Elecsys Amyloid Plasma Panel, Roche’s blood-based biomarker test designed to enable earlier Alzheimer’s disease diagnoses. Breakthrough device designation is granted to medical devices that provide a more effective way of treating or diagnosing a life-threatening…

Repeated dosing of ACD856, an investigational therapy for Alzheimer’s disease, was generally safe and well tolerated in healthy adult volunteers, according to data from a now-completed Phase 1 trial. AlzeCure Pharma is developing ACD856 as its lead therapeutic candidate in the company’s NeuroRestore platform, which contains investigational therapies for…

C2N Diagnostics has developed a new assay that precisely measures blood levels of four forms of tau, a protein involved in the brain changes observed in Alzheimer’s disease. Called the plasma tau multianalyte assay (p-tau MAA), the test is intended to be used for research purposes only and…

An investigational gamma-secretase modulator designed for the treatment of Alzheimer’s disease led to an efficient and long-lasting reduction of toxic amyloid-beta 42 peptide in cell cultures and mouse brain cells, according to data from a recent study. In mice, the compound, called AC-0027875, was also able to penetrate the…

The therapeutic candidate allopregnanolone is safe and well-tolerated in people with early Alzheimer’s disease, according to data from a Phase 1b/2a clinical trial that also investigated the medication’s maximum-tolerated dose. Moreover, MRI scans showed that allopregnanolone — dubbed ALLO by researchers — may protect against brain tissue loss…

ABvac40, an investigational vaccine, was safe and led to antibodies forming against the toxic amyloid-beta 40 peptide in people with Alzheimer’s disease, according to data from a Phase 2 trial. ABvac40’s developer, Araclon Biotech, has also made progress in developing a blood test to detect Alzheimer’s in…

Sciensus Rare, a Dutch healthcare group, was given rights to distribute CogniCann, MGC Pharmaceutical’s cannabinoid-based investigative treatment for people with dementia and Alzheimer’s disease in Europe, should it be approved for commercial use or use in select early access programs. The agreement stipulates that Sciensus Rare will have four…

NNI-362, Neuronascent’s investigational treatment for Alzheimer’s disease, was safe and reduced blood levels of an Alzheimer’s biomarker in a Phase 1a trial of the therapy in healthy, older adults. The primary goal of the trial (NCT04074837), which enrolled 56 adults between the ages of 50 and 72, was…

Treatment with the investigational candidate SAGE-718 was generally well-tolerated and associated with cognitive improvements in people with Alzheimer’s disease, according to preliminary results from the LUMINARY Phase 2 clinical trial. The therapy’s developer, Sage Therapeutics, presented these findings in a talk, titled “SAGE-718 in…